P2, N=25, Not yet recruiting, Nantes University Hospital

P4, N=202, Completed, Hospital de Clinicas de Porto Alegre | Unknown status --> Completed

P=N/A, N=100, Completed, Ain Shams Maternity Hospital

P=N/A, N=0, Withdrawn, Zimmer Biomet | N=108 --> 0 | Not yet recruiting --> Withdrawn

This case illustrates the potential limits of monotherapy with beta-lactams in native joint infections caused by G. haemolysans, especially in immunocompromised patients. The failure of amoxicillin may be explained by factors such as limited diffusion into joint tissues, the absence of surgical debridement, and the use of pharmacokinetic and pharmacodynamic breakpoints not specifically validated for this rare species. Early reassessment and combination therapy may be warranted, particularly in immunocompromised individuals.

P4, N=1770, Active, not recruiting, Duke University | Trial completion date: Aug 2025 --> Dec 2025

Burkitt lymphoma is a high-grade lymphoma with a large tumor burden and, thus, high risk for tumor lysis syndrome. Fortunately, Burkitt lymphoma has superior survival outcomes in pediatrics with a two-year survival rate estimated to be 89% and requiring minimal cycles of chemotherapy. This case underscores the diverse presentations of Burkitt lymphoma and the importance of including it in the differential for all pediatric neck masses, regardless of demographics.

The normal group mice received 0.2 mL normal saline twice a day, while the model, high-dose, and low-dose groups received 0.2 mL of an antibiotic mixture (550 mg∙kg-1 amoxicillin, 450 mg∙kg-1 clindamycin, 400 mg∙kg-1 streptomycin) twice daily to reduce AAD. Metabolomics of W. coagulans BC-G44 culture supernatants, including untargeted metabolites and Kyoto Encyclopedia of Genes and Genomes pathway annotations, revealed changes in metabolic pathways and metabolites relevant to mice. Our findings indicated that W. coagulans BC-G44 alleviates the AAD process in mice by relieving diarrhea symptoms, easing intestinal inflammation, altering intestinal permeability, and improving gut microbiota structure.

P4, N=72, Recruiting, University of Missouri-Columbia | Trial completion date: Sep 2026 --> Aug 2027 | Trial primary completion date: Sep 2025 --> Jul 2027

P=N/A, N=200, Recruiting, Bausch Health Americas, Inc. | Not yet recruiting --> Recruiting

P=N/A, N=30, Recruiting, Semmelweis University | Not yet recruiting --> Recruiting

P=N/A, N=200, Not yet recruiting, Bausch Health Americas, Inc.